In response to the COVID-19 pandemic, ACMT is collaborating with national and international partner societies as well as members of the Global Clinical Toxicology Community to offer periodic web-based presentations, panel discussions, and briefings. Subject-matter experts and practitioners, many of whom are caring for COVID-19 patients, will present on emerging issues related to COVID-19, provide updates on what they are facing in their clinics and hospitals, and participate in a Q and A.
The goal of these web-based communications is to provide timely, critical, and science-practice-based information to those who are part of the global response to this pandemic and caring for COVID-19 patients.
Interested in receiving emails about upcoming webinars?
Want a summary of this webinar series in one handy document?
Wednesday, August 19, 3:00 pm ET
PPE: Elastomeric Half-Mask Respirators
Wednesday, September 2, 3:00 pm ET
8/05/2020 - Racial & Ethnic Disparities and COVID-19
7/29/2020 - Reopening Schools During COVID-19
6/03/2020 - Inflammatory Response in Children & Adults
5/27/2020 - Pulmonary Manifestations of COVID-19
5/06/2020 - Disinfectant Update & Preservation of PPE
4/29/2020 - SARS-CoV-2 Testing
4/24/2020 - Special Event: PPE Town Hall Q&A
4/22/2020 - FDA Regulatory Toolbox
4/15/2020 - Poison Center Response
4/08/2020 - Masks & PPE
4/01/2020 - ACEs/ARBs, NSAIDS, Remdesivir
3/26/2020 - Telehealth During COVID-19
3/25/2020 - Chloroquine & Hydroxychloroquine
WEBINAR SERIES PARTNERS
American Academy of Clinical Toxicology (AACT) | American Academy of Emergency Medicine (AAEM) | American Academy of Emergency Nurse Practitioners (AAENP)| American Association of Poison Control Centers (AAPCC) | Asia Pacific Association of Medical Toxicologists (APAMT) | Emergency Nurses Association (ENA) | European Association of Poison Centers and Clinical Toxicologists (EAPCCT) | Middle East & North Africa Clinical Toxicology Association (MENATOX)
Funding for this initiative was made possible in part by an Independent Medical Education grant (No. 60970165) by Pfizer, Inc.